These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21488143)

  • 1. Metabolic tests to determine risk for type 1 diabetes in clinical trials.
    Greenbaum CJ; Buckingham B; Chase HP; Krischer J;
    Diabetes Metab Res Rev; 2011 Sep; 27(6):584-9. PubMed ID: 21488143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.
    Sosenko JM; Palmer JP; Greenbaum CJ; Mahon J; Cowie C; Krischer JP; Chase HP; White NH; Buckingham B; Herold KC; Cuthbertson D; Skyler JS
    Diabetes Care; 2006 Mar; 29(3):643-9. PubMed ID: 16505520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
    Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
    Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.
    Ryan EA; Lakey JR; Rajotte RV; Korbutt GS; Kin T; Imes S; Rabinovitch A; Elliott JF; Bigam D; Kneteman NM; Warnock GL; Larsen I; Shapiro AM
    Diabetes; 2001 Apr; 50(4):710-9. PubMed ID: 11289033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of insulin administration during the mixed meal tolerance test.
    Besser RE; Jones AG; McDonald TJ; Shields BM; Knight BA; Hattersley AT
    Diabet Med; 2012 Oct; 29(10):1279-84. PubMed ID: 22435709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance.
    Hao W; Greenbaum CJ; Krischer JP; Cuthbertson D; Marks JB; Palmer JP
    Diabetes Care; 2015 May; 38(5):891-6. PubMed ID: 25720600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.
    Sosenko JM; Palmer JP; Rafkin-Mervis L; Krischer JP; Cuthbertson D; Matheson D; Skyler JS
    Diabetes Care; 2008 Nov; 31(11):2188-92. PubMed ID: 18650369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1).
    Sosenko JM; Skyler JS; Krischer JP; Greenbaum CJ; Mahon J; Rafkin LE; Cuthbertson D; Cowie C; Herold K; Eisenbarth G; Palmer JP;
    Diabetes; 2010 Oct; 59(10):2386-9. PubMed ID: 20682683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men.
    Chen KW; Boyko EJ; Bergstrom RW; Leonetti DL; Newell-Morris L; Wahl PW; Fujimoto WY
    Diabetes Care; 1995 Jun; 18(6):747-53. PubMed ID: 7555498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion.
    Cretti A; Lehtovirta M; Bonora E; Brunato B; Zenti MG; Tosi F; Caputo M; Caruso B; Groop LC; Muggeo M; Bonadonna RC
    Eur J Clin Invest; 2001 May; 31(5):405-16. PubMed ID: 11380592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance.
    Bock G; Dalla Man C; Campioni M; Chittilapilly E; Basu R; Toffolo G; Cobelli C; Rizza R
    Diabetes; 2006 Dec; 55(12):3536-49. PubMed ID: 17130502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
    Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
    Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.
    Sosenko JM; Krischer JP; Palmer JP; Mahon J; Cowie C; Greenbaum CJ; Cuthbertson D; Lachin JM; Skyler JS;
    Diabetes Care; 2008 Mar; 31(3):528-33. PubMed ID: 18000175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series.
    Shankar SS; Vella A; Raymond RH; Staten MA; Calle RA; Bergman RN; Cao C; Chen D; Cobelli C; Dalla Man C; Deeg M; Dong JQ; Lee DS; Polidori D; Robertson RP; Ruetten H; Stefanovski D; Vassileva MT; Weir GC; Fryburg DA;
    Diabetes Care; 2016 Sep; 39(9):1602-13. PubMed ID: 27407117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of beta cell function in type 1 diabetes mellitus.
    Vendrame F; Zappaterreno A; Dotta F
    Minerva Med; 2004 Apr; 95(2):79-84. PubMed ID: 15272242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of genetic prediabetic south Indian subjects. Importance of hyperinsulinemia and beta-cell dysfunction.
    Snehalatha C; Ramachandran A; Satyavani K; Latha E; Viswanathan V
    Diabetes Care; 1998 Jan; 21(1):76-9. PubMed ID: 9538973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic.
    Hope SV; Knight BA; Shields BM; Hattersley AT; McDonald TJ; Jones AG
    Diabet Med; 2016 Nov; 33(11):1554-1558. PubMed ID: 27100275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent measures of insulin secretion and insulin sensitivity during the same test: the glucagon-insulin tolerance test.
    Dorkhan M; Tripathy D; Malm G; Asgharian H; Tuomi T; Groop L
    J Intern Med; 2008 Jul; 264(1):62-71. PubMed ID: 18298489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.
    Jones IR; Owens DR; Vora J; Luzio SD; Hayes TM
    Diabetes Res Clin Pract; 1989 Nov; 7(4):263-9. PubMed ID: 2693029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.